Age-Related Macular Degeneration Clinical Trials

106 recruitingLast updated: June 17, 2026

There are 106 actively recruiting age-related macular degeneration clinical trials across 46 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1, Phase 4. Top locations include Sacramento, California, United States, Austin, Texas, United States, Dallas, Texas, United States. Updated daily from ClinicalTrials.gov.


Age-Related Macular Degeneration Trials at a Glance

106 actively recruiting trials for age-related macular degeneration are listed on ClinicalTrialsFinder across 6 cities in 46 countries. The largest study group is Phase 2 with 25 trials, with the heaviest enrollment activity in Sacramento, Austin, and Dallas. Lead sponsors running age-related macular degeneration studies include Hoffmann-La Roche, EyeBiotech Ltd., and Adverum Biotechnologies, Inc..

Browse age-related macular degeneration trials by phase

Treatments under study

About Age-Related Macular Degeneration Clinical Trials

Looking for clinical trials for Age-Related Macular Degeneration? There are currently 54 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Age-Related Macular Degeneration trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Age-Related Macular Degeneration clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 106 trials

Recruiting
Phase 1

Phase 1 Study of C.001 in Retinal Degeneration

Geographic AtrophyAge-Related Macular DegenerationStargardt Disease+1 more
Cellio Therapeutics Inc15 enrolled1 locationNCT07594236
Recruiting
Phase 4

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Neovascular Age-related Macular Degeneration
Genentech, Inc.188 enrolled51 locationsNCT04853251
Recruiting
Phase 3

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular DegenerationnAMD
Amgen304 enrolled18 locationsNCT07614776
Recruiting

Real-world Study of Aflibercept 8 mg in nAMD

Neovascular Age-Related Macular Degeneration (nAMD)
Peking University People's Hospital300 enrolled27 locationsNCT07640997
Recruiting
Not Applicable

Village-Integrated Eye Worker Trial II

Age-Related Macular DegenerationDiabetic RetinopathyGlaucoma
University of California, San Francisco60,200 enrolled1 locationNCT03752840
Recruiting

A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

Neovascular Age-related Macular DegenerationDiabetic Macular Edema
Hoffmann-La Roche850 enrolled59 locationsNCT06680817
Recruiting
Phase 3

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular DegenerationnAMD
Hoffmann-La Roche68 enrolled16 locationsNCT05562947
Recruiting

National Eye Institute Biorepository for Retinal Diseases

Age-Related Macular DegenerationDiabetic RetinopathyRetinal Disease+2 more
National Eye Institute (NEI)650 enrolled1 locationNCT01496625
Recruiting
Phase 2

Ixoberogene Soroparvovec (Ixo-vec) Contralateral Dosing Study in Participants With Neovascular Age-related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Adverum Biotechnologies, Inc.15 enrolled4 locationsNCT07630649
Recruiting
Phase 3

Extension Study for the Port Delivery System With Ranibizumab (Portal)

Neovascular Age-related Macular Degeneration
Hoffmann-La Roche1,000 enrolled165 locationsNCT03683251
Recruiting

Visual Rehabilitation and Depression in Visually Impaired Patients With AMD

AnxietyDepression DisordersAMD - Age-Related Macular Degeneration
Fondazione G.B. Bietti, IRCCS22 enrolled1 locationNCT06906003
Recruiting

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)
Bayer50,000 enrolled1 locationNCT07308639
Recruiting
Phase 3

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration
AbbVie561 enrolled128 locationsNCT07007065
Recruiting
Phase 3

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

Neovascular Age-related Macular Degeneration
Hoffmann-La Roche250 enrolled57 locationsNCT06847542
Recruiting
Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled46 locationsNCT07482176
Recruiting
Phase 1Phase 2

Phase 1b/2a Study of EYC-0305 in Patients With Neovascular Age-related Macular Degeneration

Neovascular (Wet) Age-related Macular Degeneration
Eyconis INC.30 enrolled5 locationsNCT07587515
Recruiting
Phase 3

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Neovascular Age-related Macular Degeneration
Jaeb Center for Health Research600 enrolled65 locationsNCT05904028
Recruiting
Phase 1

Safety of BBC1501 Intravitreal Injection in Patients With Neovascular Age-Related Macular Degeneration (nAMD)

Age-Related Macular Degeneration
Benobio Co., Ltd.18 enrolled2 locationsNCT05803785
Recruiting
Early Phase 1

The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma

Age-Related Macular Degeneration
MCPHS University50 enrolled1 locationNCT06593405
Recruiting

Adaptive Optics Imaging of Outer Retinal Diseases

Age-Related Macular DegenerationRetinal DegenerationRetinitis Pigmentosa+7 more
Food and Drug Administration (FDA)100 enrolled2 locationsNCT05355415